CTIS.eu › Cities › Spain › Sevilla
Sevilla
Spain
1,630 total trials
639 recruiting
Filter these 1,630 trials by phase, condition, sponsor and more.
Open in Search →
2024-510644-31-00
3
2022-06-10
Relapsed/Refractory Multiple Myeloma
2024-516166-11-00
5
2022-06-06
Platinum resistant recurrent or metastatic ovarian, fallopian, or prim
2024-511561-10-00
4
2022-05-31
Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
2023-508954-25-00
7
2022-05-11
Advanced solid tumors (squamous cell carcinoma of the head and neck
(S
2024-511996-13-00
5
2022-05-11
Previously untreated, unresectable, or metastatic melanoma
2024-515090-96-00
11
2022-05-10
Thyroid Eye Disease
2024-510872-18-00
4
2022-05-09
Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (
2024-515832-59-00
5
2022-05-03
Bullous Pemphigoid
2023-508454-26-00
6
2022-05-01
Acute Ischemic Stroke
2023-508571-37-00
4
2022-04-29
Geographic atrophy (GA) secondary to Age-related Macular Degeneration
2023-509141-12-00
4
2022-04-28
Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH
2023-506278-10-00
5
2022-04-22
Eosinophilic esophagitis
2023-504825-38-00
4
2022-04-15
Lupus Nephritis (LN)
Immunoglobulin A Nephropathy (IgAN)
2024-514372-40-00
5
2022-04-12
Anterior ST-Elevation Myocardial Infarction
2024-511263-28-00
6
2022-04-08
Hypercholesterolemia
2024-511560-93-00
5
2022-03-29
Schizophrenia
2023-505975-54-00
5
2022-03-28
Multiple Sclerosis (MS)
2023-508828-35-01
5
2022-03-28
Patients with advanced hormone receptor-positive/HER2- negative/HER2-E
2024-511875-14-00
4
2022-03-24
Pre and post-menopausal women and men with unresectable locally advanc
2023-506074-12-00
5
2022-03-22
Metastatic Non-Small Cell Lung Cancer
2023-509917-35-00
4
2022-03-21
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (
2024-513304-33-00
5
2022-03-17
Type 1 diabetes mellitus
2024-518877-33-00
4
2022-03-17
Metastatic Colorectal Cancer
2023-503869-34-00
1
2022-03-15
Acute myeloid leukemia or myelodysplastic syndrome of high risk group,
Showing 1,465–1,488 of 1,630 trials